EP Patent

EP4678635A1 — Crystal form of nirogacestat dihydrobromate, and preparation method therefor and use thereof

Assigned to Crystal Pharmaceutical Suzhou Co Ltd · Expires 2026-01-14 · 0y expired

What this patent protects

Novel crystalline forms of Nirogacestat dihydrobromide and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing γ-secretase inhibitor drugs and drugs for treating desmoid tumors.

USPTO Abstract

Novel crystalline forms of Nirogacestat dihydrobromide and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing γ-secretase inhibitor drugs and drugs for treating desmoid tumors.

Drugs covered by this patent

Patent Metadata

Patent number
EP4678635A1
Jurisdiction
EP
Classification
Expires
2026-01-14
Drug substance claim
No
Drug product claim
No
Assignee
Crystal Pharmaceutical Suzhou Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.